Dodekin is a fully-human antibody-cytokine fusion consisting of the immunostimulatory cytokine interleukin 12 (IL12) fused to a human vascular targeting antibody. IL12 has potent anti-cancer activity, but its therapeutic use is limited by associated toxicities. However, the site-selective delivery of IL12 to the sub-endothelial extracellular matrix in tumor blood vessels allows to drastically improve the therapeutic index of this cytokine. Furthermore, the newly developed single-chain format of the antibody-cytokine fusion greatly improves the process development of Dodekin.

Quantitative biodistribution studies of Dodekin have shown a preferential uptake of the molecule in tumor tissues compared to healthy organs and our pre-clinical work shows that the immunocytokine has a potent anti-tumor activity in several immunocompetent murine models of cancer. Dodekin is able to induce long-lasting tumor eradication when administered in combination with paclitaxel, and potentiates the action of other therapeutic agents such immunological checkpoint inhibitors.

  • A clinical trial application for a Phase I study with Dodekin is currently under evaluation.


Mosely (2017) Cancer Immunol. Res., 5, 29
Hemmerle & Neri (2014) Int. J. Cancer, 134, 467
Lasek et al. (2014) Cancer Immunol. Immunother., 63, 419
Pasche et al. (2012) Clin. Cancer Res., 12, 4092
Sommavilla et al. (2010) Protein Engin. Des. Sel., 23, 653
Gafner et al. (2006) Int. J. Cancer., 119, 2205
Halin et al. (2003) Cancer Res., 63, 3202
Halin et al. (2002) Nature Biotechnol., 20, 264
Castellani et al. (2002) Am. J. Pathol., 161, 1695

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies.

I Accept Cookie Policy